Mr. Carlton is an experienced leader in the medical device industry. In addition to his role as CEO at EBT Medical, he is Co-founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm focusing on companies in the medical device space. Prior to his role at EBT Medical, he was President and CEO of HUINNO Inc., a digital healthcare company focused on improving the management and cost of hypertension through wearable technology and software.
Mr. Carlton came to Boston Scientific via the acquisition of Intelect Medical, where he served as both Co-Founder and Vice President of Product Development. While at Boston Scientific Neuromodulation, Mr. Carlton held multiple positions including Director of New Therapy Development where he focused on pain, deep brain stimulation, overactive bladder, and more.
At the start of his career, he held various roles at Medtronic, co-inventing the InterStim™ tined lead and developing InterStim™ II for the treatment of overactive bladder. He also served as Director of Engineering at Texcel Medical (Cirtec Medical).
Holding over 50 patents around electrical stimulations products and therapies, Mr. Carlton has a dual BS in Biomedical Engineering and Engineering Mechanics from The John Hopkins University. He also holds an MBA from Boston University.
Professor Yoo has spent nearly 3 decades researching diverse areas of peripheral nerve stimulation therapies, such as neural control of lower urinary function, obstructive sleep apnea, and chronic heart failure.
In addition to academic research, Dr. Yoo has worked on a number of projects within the medical device space working with such companies as Imthera Medical Inc, Microtransponder Inc., Ethicon Endosurgery, Boston Scientific Corporation, and Nuviant Medical.
Prior to joining the University of Toronto in 2012, Dr. Yoo worked both as a post-doctoral research associate and assistant research professor at Duke University under Warren Grill. Dr. Yoo received his BASc from the University of Toronto in Engineering Science (Biomedical Option), MS in Biomedical Engineering from the University of Southern California, and PhD from Case Western Reserve University in Biomedical Engineering.
Beyond his experienced background as an entrepreneur, Dr. John is the sole inventor on the first patents for statistical closed-loop neurostimulation which were licensed into Neuropace’s FDA approved treatment for epilepsy. He is a co-inventor in an EEG-based hearing assessment technology acquired by Bio-logic Systems Corp. This technology became the company’s best-selling product before its acquisition by Natus.
He holds 85+ patents and has been an IP strategy consultant in the areas of neurostimulation, neurodiagnostics, wireless power transmission, and renal nerve ablation. As Chief Scientific Officer for AngelMed, he helped obtain FDA approval of the world’s first implantable heart-attack detector. In addition, he has led publication, clinical trial design, and market access strategies.
Dr. John has lectured on medical commercialization at the IBBME (University of Toronto) since 2007. He holds an MSc in Psychiatry (McGill) and a PhD in Medical Science (University of Toronto).
Mr. Labbe’s expertise spans across all phases of product development, including clinical inputs, product definition, system architecture, detailed multi-disciplinary product development, V&V testing, regulatory submissions and manufacturing design transfer.
Prior to EBT Medical, he served as the Director of Engineering for Valtronic, a device design and manufacturing company specializing in complex medical electromechanical systems.
Mr. Labbe also held the role of Director of R&D at Nuvectra, Greatbatch Medical/Integer Holding’s neuromodulation spinout company. There he was responsible for the ground-up development and commercialization of a novel 24-channel, fully implantable neurostimulation system with applications in the treatment of chronic pain, overactive bladder, and deep brain applications for movement disorders. He excelled as the VP of Engineering for BIOMEC, where he grew and managed a startup engineering team through the submission, receipt and execution of over $30M in NIH funding for various product development programs, prior to BIOMEC’s eventual acquisition.
Mike earned a BS in Electrical Engineering from Worcester Polytechnic Institute and an MS in Biomedical Engineering from Case Western Reserve University.
Mr. Mariash’s impressive career in marketing, commercialization and strategy spans two decades. Before joining EBT Medical, he was the commercial lead for Boston Scientific’s Cosman radiofrequency ablation franchise. He also led Strategy for Boston Scientific’s ~$1B Neuromodulation division, shaping portfolio and digital strategy, owning business planning, and driving M&A assessments. As commercial owner, he also oversaw development of various Class II & III devices.
Mr. Mariash started his career in management consulting at Charles River Associates, also spending time at CSL, Ltd (Australia’s largest biotech) and at Baxter BioScience, with leadership roles in marketing, strategy, and corporate development.
Mr. Mariash brings a wealth of expertise in neuromodulation, product development, market insights, go-to-market (including digital), and scaling WW commercial operations. He has degrees in Business Economics and Biochemistry from Brown University.
Dr. Roychowdhury has an established track record of successful ‘concept to market’ clinical development experience across a range of single-use and implantable medical devices, capital equipment, and drug-device combination products.
Before joining EBT Medical, he held high-level leadership positions in Clinical, Regulatory, and R&D for Cantel Medical, Cogentix Medical, and American Medical Systems (now Boston Scientific).
Beyond urology, Dr. Roychowdhury has successfully led products through clinical development and commercial introduction for the Cardiology, Peripheral Vascular, Orthopedic/Spine and Infection Prevention and Control spaces.
Dr. Roychowdhury is an inventor on more than 25 patents. He has MS. and PhD. degrees in Materials Science and Engineering from the University of Delaware, and a BS in Metallurgical Engineering from the Indian Institute of Technology (BHU).
In addition to her wide range of experience in the medical device industry, Dr. Baynham also founded Ingenuity Medical Device Research, LLC, providing intellectual property development, pre-clinical and clinical study development, and medical writing services. Her clinical research experience encompasses Phase 1 -4 studies in cardiovascular (post-MI, angina, and heart failure) and neuromodulation (vagus nerve stimulation for obesity and heart failure, transcutaneous sacral neuromodulation for overactive bladder, transcutaneous peripheral stimulation for obesity, spinal cord stimulation for pain).
Dr. Baynham is also a patent agent registered to practice at the United States Patent and Trade Organization (USPTO). She currently holds over 40 patents granted by the USPTO in the areas of electrical stimulation and neuromodulation therapies.
Dr. Baynham earned her undergraduate degree in Biomedical and Electrical Engineering at Vanderbilt University and her MS and PhD in Biomedical Engineering at The University of Alabama at Birmingham.
Mr. Nataranjan advises several Toronto-based start-up companies on strategy, growth, geographical diversification & funding. He also serves as advisor to Angel Funds and sits on the boards of several start-ups. He is a partner in Formulate IP, a global Intellectual Property Advisory firm.
Mr. Nataranjan was previously CFO of Consumer division of Johnson & Johnson Inc, Canada, where he played a critical role in driving profitable growth, finance transformation, acquisition and integration. Prior to his move to the Consumer Sector in JNJ, he was a Director at the Janssen Pharmaceutical division of JNJ.
Mr. Nataranjan is a Wharton Alumni and CPA, CA.